Blog

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Photo from Giuseppe Curigliano/X

Jun 5, 2024, 05:51

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: .

“Congratulations to Giuseppe Curigliano for the outstanding presentation of the DESTINY-Breast06 trial at the ASCO Annual Meeting.

The improvement in progression-free survival in the group of patients treated with trastuzumab deruxtecan (T-DXd, Enhertu) compared to conventional chemotherapy is statistically significant and clinically meaningful.

Practice changing study!”

No alternative text description for this image

Source: Francisco J. Esteva/LinkedIn

ASCO ASCO24 cancer conventional chemotherapy DESTINY-Breast06 Trial Enhertu Francisco J. Esteva Giuseppe Curigliano Lenox Hill Hospital OncoDaily Oncology T-Dxd Trastuzumab deruxtecan

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more